- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06173518
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients With CD19-Positive Relapsed/ Refractory (r/r) B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-arm, open-label, multi-center, Phase Ib study to determine the safety and preliminary efficacy of AUTO1 administered intravenously in pediatric patients with r/r B ALL and with r/r aggressive mature B NHL. This study is designed to evaluate the safety and preliminary efficacy of AUTO1.
The safety and tolerability of AUTO1 in pediatric patients will be continually monitored by the Sponsor. Additionally, the Independent Data Monitoring Committee (IDMC) will review the rolling safety data generated after 6 and 12 treated patients have been monitored for at least 28 days and in the event any protocol defined safety stopping criteria are met. If no pre-defined safety events related to AUTO1 are met, and the safety data are consistent with what has previously been observed with AUTO1, the IDMC can recommend continuing the study without or with modifications. Based on emerging data, the study may be stopped early due to excessive toxicity, i.e. certain pre-defined AUTO1-related safety events or deaths.
The study will involve consented patients going through the following sequential study periods: screening, leukapheresis, bridging as necessary, pre-conditioning, treatment evaluation, and follow-up.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Autolus Ltd
- Phone Number: +44 (0) 203 911 4385
- Email: clinicaltrials@autolus.com
Study Locations
-
-
-
London, United Kingdom
- Recruiting
- Great Ormond Street Hospital For Children NHS Foundation Trust
-
Principal Investigator:
- Dr Juliana Silva, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients < 18 years old at screening
- Patients with ≥ 6 kg body weight at screening
B ALL Cohort: r/r CD19-positive B ALL defined as:
- Primary refractory disease defined as:
- Children's Oncology Group (COG) very high risk first relapse if first remission ≤18 months.
- Relapsed or refractory disease after two or more lines of systemic therapy.
- Relapsed or refractory disease after allogeneic transplant provided AUTO1 infusion occurs at least 3 months after stem cell transplant..
- Any of the above with Philadelphia chromosome positive disease (Ph+ ALL) where patient is intolerant to or has failed two lines of any tyrosine kinase inhibitor (TKI) or one line of second-generation TKI, or if TKI therapy is contraindicated
B NHL Cohort: r/r CD19-positive aggressive mature B NHL defined as:
- Relapsed after one or more prior therapies (can include allogeneic and autologous hematopoietic stem cell transplant)
- Primary refractory (have not achieved a complete or partial response after the first line of therapy) with measurable, biopsy-proven disease by radiological criteria at screening including the B NHL subtypes diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) and high-grade B-cell lymphoma (not otherwise specified)
- Karnofsky (age ≥ 10 years) or Lansky (age < 10 year) performance status score ≥ 50%.
- Local documentation of CD19 expression on leukemic blasts in the BM, peripheral blood, or cerebrospinal fluid (CSF) or biopsy within 30 days of consent
- Adequate renal, hepatic, pulmonary, and cardiac function
Exclusion Criteria:
- Diagnosis of chronic myelogenous leukemia lymphoid in blast crisis
- History or presence of clinically relevant central nervous system (CNS) pathology
- Presence of CNS 3 disease or CNS 2 disease with neurological changes at screening
- Presence of active or uncontrolled fungal, bacterial, viral, or other infection requiring systemic antimicrobials for management
- Patients who had prior (less than 3 months before AUTO 1 infusion) stem cell transplant
- Prior CD19 targeted therapy other than blinatumomab
- Patients who have experienced Grade 3 or higher neurotoxicity following blinatumomab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AUTO1
|
Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and severity of adverse events (AE) and serious adverse events (SAE)
Time Frame: Up to 24 months
|
Up to 24 months
|
Incidence of severe hypogammaglobulinemia
Time Frame: Up to 24 months
|
Up to 24 months
|
Duration of severe hypogammaglobulinemia
Time Frame: Up to 24 months
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall remission rate in B ALL patients
Time Frame: Up to 24 months
|
Defined as best response of complete remission or complete remission with incomplete recovery of counts per Investigator assessment occurring at any time after AUTO1 infusion
|
Up to 24 months
|
Overall response rate in B NHL patients
Time Frame: Up to 24 months
|
Defined as best response of complete response or partial response per Investigator assessment occurring at any time after AUTO1 infusion
|
Up to 24 months
|
Duration of remission in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Duration of response in B NHL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Overall survival in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Overall survival in B NHL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Incidence of CD19-negative relapse at any time in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Incidence of CD19-negative relapse at any time in B NHL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Event-free survival in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Proportion of patients achieving minimal residual disease (MRD)-negative remission in BM within 3 months of AUTO1 dosing in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Proportion of patients achieving complete remission within 3 months per Investigator assessment in B ALL
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Progression-free survival in B NHL
Time Frame: Up to 24 months
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- B cell acute lymphoblastic leukemia
- Relapsed B cell acute lymphoblastic leukemia
- Refractory B cell acute lymphoblastic leukemia
- AUTO1
- CD19-positive CAR T cell
- Pediatric ALL
- B cell Non-Hodgkin lymphoma
- Relapsed B cell Non-Hodgkin lymphoma
- Refractory B cell Non-Hodgkin lymphoma
- Aggressive mature B cell Non-Hodgkin lymphoma
- Pediatric NHL
- Obecabtagene autoleucel
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUTO1-PY1
- 2023-506307-26-00 (Other Identifier: EU CT)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
-
Shenzhen BinDeBio Ltd.Xiangya Hospital of Central South UniversityRecruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.Children's Hospital of Fudan UniversityActive, not recruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.The First Affiliated Hospital of Zhengzhou UniversityUnknownRefractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory B-cell LymphomaChina
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health HospitalRecruitingRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin LymphomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRelapsed and/or Refractory Acute Lymphoblastic Leukemia | Relapsed and/or Refractory B-cell Non-Hodgkin's LymphomaChina
-
Verastem, Inc.WithdrawnRelapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnB-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia
-
Michael BurkeAmgenRecruitingRefractory B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic LeukemiaUnited States
-
Novartis PharmaceuticalsCompletedB-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic LeukemiaUnited States
-
Beijing Yongtai Ruike Biotechnology Company LtdRecruitingRefractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic LeukemiaChina
Clinical Trials on AUTO1
-
Autolus LimitedActive, not recruitingRelapsed or Refractory B Cell Acute Lymphoblastic LeukemiaUnited States, United Kingdom, Spain